Pazopanib HCl (GW786034 HCl)

Catalog No.S1035

Pazopanib HCl (GW786034 HCl) Chemical Structure

Molecular Weight(MW): 473.98

Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 270 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • IC50 of Pazopanib that block ANDV-induced EC permeability. Endothelial cells were ANDV infected, and 3 days postinfection the permeability of cells in response to VEGF addition was determined in the presence or absence of increasing amounts of kinase inhibitor. (B): VEGFR2-Src inhibitors block ANDV-induced permeability. Endothelial cells were plated on vitronectin-coated Transwell inserts and infected at an MOI of 0.5 in triplicate with ANDV. Three days postinfection, the permeability of ANDV- and mock-infected endothelial cell monolayers was determined at indicated times in the presence or absence of Pazopanib.

    J Virol, 2011, 85(5): 2296-303. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

    MRC5 non-transformed human lung fibroblasts were infected with influenza viruses (100 multiplicity of infection). Two hours after infection the cells were treated with vehicle control; sorafenib tosylate (2mM); pazopanib (2mM); OSU-03012 (2mM); and AR-13 (2mM). Twenty-four hours after infection the cells are treated with live/dead agent where green cells are viable and cells staining yellow or red are considered dead. Cells are examined at 10 magnification in a Hermes wide-field microscope (n¼3 SEM) P<0.05 less than vehicle control level of virus-mediated cell killing.

    J Cell Physiol, 2016, 231(10):2286-302.. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

  • Effect of HDIL-2/TKI on apoptosis of RCC cells. Three RCC cell lines treated with different concentrations of Pazopanib and HDIL-2 and incubated for 48 h. Microscopic images show apoptotic materials 48 h following treatment (arrows show the apoptotic materials in the pazopanib-treated cells).

    Expert Opin Pharmacother 2014 15(11), 1489-99. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
Features A multi-kinase inhibitor.
Targets
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
FGFR [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
In vitro

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] Pazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HUVEC M3T2cGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MVzpcohq[mm2czD0bIUhXkWJRj3pcoR2[2WmIIDyc4xq\mW{YYTpc44hd2ZiSGXWSWN{ M2\QNFE5PjJyM{iy
HUVEC NVf4VZo{U2mwYYPlJIF{e2G7 M4TnbolvcGmkaYTzJHZGT0ZvaX7keYNm\CCyaH;zdIhwenmuYYTpc44hd2ZiVlXHSnIuOiCrbjDIWXZGSyClZXzsd{B4cXSqIHHuJGlEPTBib3[g5qi9QCCwTR?= NXfKfFlLOTh4MkCzPFI>
MM MoDMT4lv[XOnIHHzd4F6 MX7pcohq[mm2czDWSWdHNWmwZIXj[YQheGixc4Doc5J6dGG2aX;uJI9nKG[udEG= NYnmO|dIOTdzNkSzN|I>
MM.1S Mmm0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NE\aRlQyOCEQvHevcWw> NV7VfHc2cW6qaXLpeJMhVU1iQ3XscEBIem:5dHi= MV2xO|E3PDN|Mh?=
MM.1R M1j5OWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MYWxNEDPxGdxbVy= M3\v[4lvcGmkaYTzJG1OKEOnbHygS5Jwf3Sq Mn;4NVcyPjR|M{K=
RPMI NUW2U5VNT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M{LCXFExKM7:Zz;tUC=> NW\sfoFncW6qaXLpeJMhVU1iQ3XscEBIem:5dHi= MnfYNVcyPjR|M{K=
Dox40 M1;RUGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NGTjNoEyOCEQvHevcWw> NVeyZ5N3cW6qaXLpeJMhVU1iQ3XscEBIem:5dHi= M1;GV|E4OTZ2M{Oy
INA-6 MoXrS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MlrsNVAh|rypL33M MnvFbY5pcWKrdIOgUW0hS2WubDDHdo94fGh? M1GwNFE4OTZ2M{Oy
OPM2 NFTE[otIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NWW0[3FnOTBizsznM41N NGrJPVhqdmirYnn0d{BOVSCFZXzsJGdzd3e2aB?= NGSyUVQyPzF4NEOzNi=>
U266 MlL5S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MXWxNEDPxGdxbVy= NH60XlFqdmirYnn0d{BOVSCFZXzsJGdzd3e2aB?= MoXHNVcyPjR|M{K=
MM.1S NW[2OWxR[3m2b4TvfIlkcXS7IHHzd4F6 NFS2TZgzOCEQvHevcWw> M3fXeYlvcGmkaYTzJG1OKEOnbHygV5Vzfmm4YXy= NHPpUnoyPzF4NEOzNi=>
MM.1R NX3OdGVC[3m2b4TvfIlkcXS7IHHzd4F6 NWXMemVEOjBizsznM41N MknrbY5pcWKrdIOgUW0hS2WubDDTeZJ3cX[jbB?= NUnlZpJnOTdzNkSzN|I>
RPMI NFf2PZFkgXSxdH;4bYNqfHliYYPzZZk> MXiyNEDPxGdxbVy= MYHpcohq[mm2czDNUUBE\WyuIGP1dpZqfmGu NHfjZmoyPzF4NEOzNi=>
Dox40 MnPrZ5l1d3SxeHnjbZR6KGG|c3H5 MoK1NlAh|rypL33M MlvYbY5pcWKrdIOgUW0hS2WubDDTeZJ3cX[jbB?= NVnU[G9LOTdzNkSzN|I>
INA-6 NVfRUIo4[3m2b4TvfIlkcXS7IHHzd4F6 NHXVVnYzOCEQvHevcWw> NHnWeXZqdmirYnn0d{BOVSCFZXzsJHN2en[rdnHs MUGxO|E3PDN|Mh?=
OPM2 MYDjfZRwfG:6aXPpeJkh[XO|YYm= M3rZNlIxKM7:Zz;tUC=> M2\j[olvcGmkaYTzJG1OKEOnbHygV5Vzfmm4YXy= NFnrcnIyPzF4NEOzNi=>
U266 MWPjfZRwfG:6aXPpeJkh[XO|YYm= Mn34NlAh|rypL33M NVPxWHhNcW6qaXLpeJMhVU1iQ3XscEBUfXK4aY\hcC=> MX2xO|E3PDN|Mh?=
MM.1S Mo\zSpVv[3Srb36gZZN{[Xl? M2C4ZZN2eHC{ZYPz[ZMhXkWJRj3JcoR2[2WmIFXu[I91cGWuaXHsJGNmdGxiUILvcIln\XKjdHnvckBidmRiTXnndoF1cW:wLh?= NUX5V4RVOTdzNkSzN|I>
MM.1R NH65T3lHfW6ldHnvckBie3OjeR?= M3nuT5N2eHC{ZYPz[ZMhXkWJRj3JcoR2[2WmIFXu[I91cGWuaXHsJGNmdGxiUILvcIln\XKjdHnvckBidmRiTXnndoF1cW:wLh?= MnHyNVcyPjR|M{K=
Dox40 MlG4SpVv[3Srb36gZZN{[Xl? NIDZWId{fXCycnXzd4V{KF[HR1[tTY5lfWOnZDDFcoRwfGinbHnhcEBE\WyuIGDyc4xq\mW{YYTpc44h[W6mIF3p[5JifGmxbj6= MVyxO|E3PDN|Mh?=
OPM2 Mo\QSpVv[3Srb36gZZN{[Xl? M2K0eJN2eHC{ZYPz[ZMhXkWJRj3JcoR2[2WmIFXu[I91cGWuaXHsJGNmdGxiUILvcIln\XKjdHnvckBidmRiTXnndoF1cW:wLh?= NWi4NYhjOTdzNkSzN|I>
HBMEC NHvFZ3ZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MWX+NVAh|ryP NUnsTFVKTE2VTx?= NXnDWIVvUUN3ME2xJO69VQ>? NF\FTIQzOTB6MU[1Oi=>
HBMEC NWXxeJBRTnWwY4Tpc44h[XO|YYm= MVn+NUDPxE1? M1TaVGROW09? NYnNOGdM[WK{b3fheIV{KHSqZTDwbI9{eGixconsZZRqd25ib3[gWmVITlJ{IIfpeIgh\Gm|coXweIlwdiCxZjDkc5dve3S{ZXHtJHBNS87|MR?= NIL4VVAzOTB6MU[1Oi=>
HBMEC MV3GeY5kfGmxbjDhd5NigQ>? NGPRSVF,OSEQvF2= MVnEUXNQ MYDkbZNzfXC2czD0bIUhWmG|LWLh[k1GWkticHH0bJdigSC2aILveYdpKGSnY4LlZZNm\CCyaH;zdIhwenmuYYTl[EBOTUtzL{KgZY5lKEWUS{GvNi=> NH\GWpEzOTB6MU[1Oi=>
HBMEC NGDaWohHfW6ldHnvckBie3OjeR?= NIe5fVN,OjBizszN NV\E[nhXTE2VTx?= MWDkbZNzfXC2czC1NEUhd2ZidIXi[UBnd3KvYYTpc44h[XRiMTFOwG0> NF;1WJkzOTB6MU[1Oi=>
MDA-MB-231 M4D2[Gdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MVH+NVAh|ryP NYXWe3hmTE2VTx?= MmD3TWM2OD13IN88US=> NFn6W4MzOTB6MU[1Oi=>
MDA-MB-231 MnyzSpVv[3Srb36gZZN{[Xl? NETmUGMxNjVizszN M3LIdWROW09? NWrre|NvcW6qaXLpeJMhfGinIFXST|EwOiC|aXfuZYxqdmdicHH0bJdigQ>? M{jROVIyODhzNkW2
MDA-MB-231 M13YN2Z2dmO2aX;uJIF{e2G7 NWPteWdRPSEQvF2= M2G2e2ROW09? NVv5O3BXcW6mdXPld{BiKGOnbHytZ5lkdGViYYLy[ZN1 MXyyNVA5OTZ3Nh?=
J82 NHH4PG5kgXSxdH;4bYNqfHliYYPzZZk> M{HPWZ4yOCEQvF2= NInuXYxFVVOR MoLWTWM2OD1{ND61O{DPxE1? NUfsWXRKOjF3Mkm5NFA>
T24 NF3VRVhkgXSxdH;4bYNqfHliYYPzZZk> NVnuVlJphjFyIN88US=> MX;EUXNQ NY\MboF[UUN3ME21Nk41PSEQvF2= MXmyNVUzQTlyMB?=
HT1376 NGDsRYVkgXSxdH;4bYNqfHliYYPzZZk> NXjjOIxJhjFyIN88US=> MnfaSG1UVw>? M{XLemlEPTB;MkiuNlEh|ryP NUHhOoR7OjF3Mkm5NFA>
RT4 M{\ReYN6fG:2b4jpZ4l1gSCjc4PhfS=> NGnD[4R,OTBizszN M{DiPGROW09? MoK3TWM2OD13LkG0JO69VQ>? M4nkPVIyPTJ7OUCw
CRL1749 MmH2Z5l1d3SxeHnjbZR6KGG|c3H5 NUfle|cyhjFyIN88US=> M4rWdmROW09? MVjJR|UxRTJ{Lk[5JO69VQ>? NXjTPVZWOjF3Mkm5NFA>
HTB9 MonQZ5l1d3SxeHnjbZR6KGG|c3H5 NYjocWhlhjFyIN88US=> MnSxSG1UVw>? NWf3V3d3UUN3ME2xNU45PCEQvF2= MlnQNlE2Ojl7MEC=
Sup NXvyeo41[3m2b4TvfIlkcXS7IHHzd4F6 MWD+NVAh|ryP NFnETodFVVOR NUK4S5Z[UUN3ME21N{4{OiEQvF2= NWOzcIJtOjF3Mkm5NFA>
HTB3 MnXUZ5l1d3SxeHnjbZR6KGG|c3H5 NYDreFJEhjFyIN88US=> NEnRdmpFVVOR Mn3yTWM2OD1zND6xOkDPxE1? M1zlc|IyPTJ7OUCw
CEC M1fKOGZ2dmO2aX;uJIF{e2G7 NXLXdlJyhjFyIN88[{9uVA>? M1TLZWROW09? NIHyPFdld3ewLYLl[5Vt[XSnczDWSWdHKGyndnXsdy=> M4q3T|IyPjJyOEKy
RPE MX\GeY5kfGmxbjDhd5NigQ>? MXr+NVAh|rypL33M MmPtSG1UVw>? MWrkc5dvNXKnZ4XsZZRmeyCYRVfGJIxmfmWucx?= M4mxSFIyPjJyOEKy
CEC MVnGeY5kfGmxbjDhd5NigQ>? NEjlSYZ,PSEQvHevcWw> MnGwSG1UVw>? MWDicI9kc3NiZX7kc5Rp\WyrYXygZ4VtdCCvaXfyZZRqd25? M{K0XFIyPjJyOEKy
5637 MlHES5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NXLYNZVsTE2VTx?= MmXBTWM2OD1zNT6w5qCK|ryP NFPIT3QzOzh6N{[wOS=>
J82 M{fWc2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M2nqTGROW09? M2ThfmlEPTB;MUiuOQKBkc7:TR?= NVHNWYVtOjN6OEe2NFU>
5637 NX3TSYhuSXW2b4DoZYd6KGG|c3H5 NX3qb41wOjBizszN MYDEUXNQ MXH0dolo\2W{czD0bIUh[XW2b4DoZYdq[yCycn;j[ZN{ MWSyN|g5PzZyNR?=
J82 M3HjcmF2fG:yaHHnfUBie3OjeR?= MmjjNlAh|ryP MXrEUXNQ M{jDdJRzcWepZYLzJJRp\SCjdYTvdIhi\2mlIIDyc4Nme3N? M{LoRVI{QDh5NkC1
5637 NEPmT5VHfW6ldHnvckBie3OjeR?= MoTzNlAh|ryP NFnkWoNFVVOR M1\XSolv\HWlZYOgcJl{d3OxbXHsMYRmeGWwZHXueEBv\WO{b4Ppdy=> M4jOU|I{QDh5NkC1
J82 NEfyUZFHfW6ldHnvckBie3OjeR?= MVeyNEDPxE1? MmDHSG1UVw>? Mn[1bY5lfWOnczDsfZNwe2:vYXyt[IVx\W6mZX70JI5m[3Kxc3nz Ml;lNlM5QDd4MEW=
5637 NVvyNpVpTnWwY4Tpc44h[XO|YYm= MXyyNEDPxE1? NE\PcHRFVVOR NUfYe3V3cW6mdXPld{BtgXOxc3;t[UBidHSncnH0bY9vKGGwZDDpcohq[mm2czDDRkBi[3Srdnn0fS=> MnLVNlM5QDd4MEW=
J82 NE\Mb3NHfW6ldHnvckBie3OjeR?= MWSyNEDPxE1? NW\NR2tGTE2VTx?= NFvXUoJqdmS3Y3XzJIx6e2:|b33lJIFtfGW{YYTpc44h[W6mIHnubIljcXS|IFPCJIFkfGm4aYT5 NYjaZo1WOjN6OEe2NFU>
KATO-II NELB[I9Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NInOUpA2KM7:TR?= NF;YcWlFVVOR MkL5Zoxw[2u|IIDyc4xq\mW{YYTpc44> NWWxVpVSOjV{NEm1OVc>
OCUM-2M MYTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NFX6NYw2KM7:TR?= NVexSGxzTE2VTx?= MXLicI9kc3NicILvcIln\XKjdHnvci=> M2PCcFI2OjR7NUW3
SNU-16 NH:5UpRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NWnxbYZzPSEQvF2= NGjsTnhFVVOR MYPicI9kc3NicILvcIln\XKjdHnvci=> M{K4VVI2OjR7NUW3
HSC-39 MY\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MmO4OUDPxE1? MmmxSG1UVw>? NEi4SmxjdG:la4OgdJJwdGmoZYLheIlwdg>? MXSyOVI1QTV3Nx?=
KATO-II Ml74Z5l1d3SxeHnjbZR6KGG|c3H5 MYj+NVAh|ryP MlzGSG1UVw>? M2HzS2lEPTB;MD6xJJRwKDJwMDFOwI1wdC:O MkX4NlUzPDl3NUe=
OCUM-2M M3jsUoN6fG:2b4jpZ4l1gSCjc4PhfS=> M3PwUZ4yOCEQvF2= MVzEUXNQ MX3JR|UxRTBwMTD0c{AzNjBizsztc4wwVA>? NWLOVYFvOjV{NEm1OVc>
SNU-16 NIjtT4FkgXSxdH;4bYNqfHliYYPzZZk> NIDI[Vl,OTBizszN MonpSG1UVw>? MmWyTWM2OD1yLkGgeI8hOi5yIN88cY9tN0x? NIr4fHkzPTJ2OUW1Oy=>
HSC-39 NVr1cVMy[3m2b4TvfIlkcXS7IHHzd4F6 NHHqZVZ,OTBizszN MXvEUXNQ NUTQOlVEUUN3ME2wMlEhfG9iMj6wJO69dW:uL1y= MoC2NlUzPDl3NUe=
NIH 3T3 NYPsVZVNT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M4nacZ4yOCEQvF2= MmDtSG1UVw>? M3Pv[IlvcGmkaYTzJINmdGxiZ4Lve5RpKGGwZDDjc4xwdnliZn;ycYF1cW:w Mnj0NlUzPDl3NUe=
KATO-III MUnGeY5kfGmxbjDhd5NigQ>? MkLSNUDPxE1? NGe5WJpFVVOR NG\mOJdqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0 MlTTNlUzPDl3NUe=
OCUM-2M Mmr0SpVv[3Srb36gZZN{[Xl? NHvSdZQyKM7:TR?= MYTEUXNQ MkDjbY5lfWOnczDj[YxtNWO7Y3zlJIFzemW|dB?= MX[yOVI1QTV3Nx?=
KATO-III NILjeWxCeG:ydH;zbZMh[XO|YYm= M1XhXVEh|ryP NVLsfXhJTE2VTx?= M2nDNYlv\HWlZYOgZZBweHSxc3nz NIHycXczPTJ2OUW1Oy=>
OCUM-2M MV3BdI9xfG:|aYOgZZN{[Xl? M{O3[lEh|ryP NVjLRm5vTE2VTx?= MkfsbY5lfWOnczDhdI9xfG:|aYO= NVHBdHlqOjV{NEm1OVc>
KATO-III M1za[WZ2dmO2aX;uJIF{e2G7 M37OOlEh|ryP MmCxSG1UVw>? MWXpcohq[mm2czDGS2ZTOiCyaH;zdIhwenmuYYTpc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7nJI1wdGWldXzldy=> NUDSe|hFOjV{NEm1OVc>

... Click to View More Cell Line Experimental Data

In vivo The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase enzyme assays:

VEGFR enzyme assays for VEGGR1, VEGFR2, and VEGFR3 are run in homogeneous time-resolved fluorescence (HTRF) format in 384-well microtiter plates using a purified, baculovirus-expressed glutathione-S-transferase (GST) fusion protein encoding the catalytic c-terminus of human VEGFR receptor kinases 1, 2, or 3. Reactions are initiated by the addition of 10 μL of activated VEGFR2 kinase solution [final concentration, 1 nM enzyme in 0.1 M HEPES, pH 7.5, containing 0.1 mg/mL bovine serum albumin (BSA), 300 μM dithiothreitol (DTT)] to 10 μL substrate solution [final concentration, 360 nM peptide, (biotin-aminohexyl-EEEEYFELVAKKKK-NH2), 75 μM ATP, 10 μM MgCl2], and 1 μL of titrated Pazopanib in DMSO. Plates are incubated at room temperature for 60 min, and then the reaction is quenched by the addition of 20 μL of 100 mM ethylene diamine tetraacetic acid (EDTA). After quenching, 20 μL HTRF reagents (final concentration, 15 nM Streptavidin-linked allophycocyanin, 1 nM Europium-labeled antiphosphotyrosine antibody diluted in 0.1 mg/mL BSA, 0.1 M HEPES, pH 7.5) is added and the plates incubated for a minimum of 10 min. The fluorescence at 665 nM is measured with a Wallac Victor plate reader using a time delay of 50 μs.
Cell Research:

[1]

+ Expand
  • Cell lines: HUVEC cells
  • Concentrations: 0-10 μM
  • Incubation Time: 1 hour
  • Method:

    Phosphorylation of VEGFR2 is assessed in HUVEC stimulated with VEGF. HUVEC are plated in type-I collagen-coated 10 cm plates in Clonetics EGM-MV medium at 1.0-1.5 × 106 cells/plate. After 24 hours, the confluent cells are serum starved overnight by replacing the growth medium with Clonetics EBM medium containing 0.1% BSA, 500 μg/mL hydrocortisone. Cells are treated with Pazopanib at various concentrations for 1 hour, followed by addition of 10 ng/mL VEGF or vehicle for 10 min. Cells are solubilized in lysis buffer. VEGFR2 is immunoprecipitated using antiflk-1 antibody and analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by Western blotting and detection with antiflk-1 or with antiphosphotyrosine (anti-P-tyr-biotin) antibody. The VEGFR2 phosphorylation level is quantified by densitometry and normalized to the total VEGFR2 level.


    (Only for Reference)
Animal Research:

[2]

+ Expand
  • Animal Models: Immunodeficient mice bearing SYO-1 cells
  • Formulation: --
  • Dosages: 0 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 17 mg/mL (35.86 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 473.98
Formula

C21H23N7O2S.HCl

CAS No. 635702-64-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01072214 Completed Macular Degeneration GlaxoSmithKline March 9 2010 Phase 1
NCT00866528 Completed Lung Cancer Non-Small Cell GlaxoSmithKline July 9 2009 Phase 1
NCT02795819 Active not recruiting Renal Cell Carcinoma|Soft Tissue Sarcoma|Metastatic Disease Virginia Commonwealth University|National Cancer Institute (NCI) July 8 2016 Phase 1
NCT02450136 Recruiting Refractory Solid Tumors Samsung Medical Center October 8 2015 Not Applicable
NCT02300545 Recruiting Sarcoma Soft Tissue|Soft Tissue Sarcoma Washington University School of Medicine April 8 2015 Phase 2
NCT01956669 Recruiting Solid Tumours Novartis Pharmaceuticals|Children''s Oncology Group|Novartis October 8 2014 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) supplier | purchase Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) cost | Pazopanib HCl (GW786034 HCl) manufacturer | order Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID